483 related articles for article (PubMed ID: 20196038)
21. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Ahrén B
Curr Diab Rep; 2007 Oct; 7(5):340-7. PubMed ID: 18173966
[TBL] [Abstract][Full Text] [Related]
22. Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Prescrire Int; 2013 May; 22(138):121. PubMed ID: 23819170
[No Abstract] [Full Text] [Related]
23. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
24. [DPP-IV inhibitors and GLP-1 analogues].
Zettl H; Steinhilber D
Pharm Unserer Zeit; 2010 Mar; 39(2):108-13. PubMed ID: 20196037
[No Abstract] [Full Text] [Related]
25. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Barnett A
Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
[TBL] [Abstract][Full Text] [Related]
26. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Fakhoury WK; Lereun C; Wright D
Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
[TBL] [Abstract][Full Text] [Related]
27. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
Halimi S; Raccah D; Schweizer A; Dejager S
Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
[TBL] [Abstract][Full Text] [Related]
28. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Scherbaum WA
Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
[No Abstract] [Full Text] [Related]
29. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
30. The physiologic role of incretin hormones: clinical applications.
Cefalu WT
J Am Osteopath Assoc; 2010 Mar; 110(3 Suppl 2):S8-S14. PubMed ID: 20382839
[TBL] [Abstract][Full Text] [Related]
31. The metabolic syndrome influences the response to incretin-based therapies.
Fadini GP; de Kreutzenberg SV; Gjini R; Avogaro A
Acta Diabetol; 2011 Sep; 48(3):219-25. PubMed ID: 21574000
[TBL] [Abstract][Full Text] [Related]
32. [Incretin related agents for treatment of diabetes mellitus].
Miyagawa J; Miuchi M; Nanba M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
[No Abstract] [Full Text] [Related]
33. The role of vildagliptin in the management of type 2 diabetes mellitus.
Kleppinger EL; Helms K
Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
[TBL] [Abstract][Full Text] [Related]
34. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
35. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
Mathieu C; Bollaerts K
Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
[TBL] [Abstract][Full Text] [Related]
36. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236
[TBL] [Abstract][Full Text] [Related]
37. Vildagliptin in clinical practice: a review of literature.
Banerjee M; Younis N; Soran H
Expert Opin Pharmacother; 2009 Nov; 10(16):2745-57. PubMed ID: 19874253
[TBL] [Abstract][Full Text] [Related]
38. [Sitagliptin].
Taéron C
Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
[No Abstract] [Full Text] [Related]
39. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
Nicolucci A; Rossi MC
Acta Biomed; 2008 Dec; 79(3):184-91. PubMed ID: 19260377
[TBL] [Abstract][Full Text] [Related]
40. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]